PAM
KERX

Paradigm Asset Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Paradigm Asset Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-21,700
Closed -$298K – 838
2014
Q3 		$298K Sell
21,700
-9,000
-29% -$138K 0.04% 425
2014
Q2 		$472K Buy
30,700
+5,200
+20% +$73.7K 0.06% 323
2014
Q1 		$435K Sell
25,500
-2,000
-7% -$30.2K 0.06% 337
2013
Q4 		$356K Buy
+27,500
New +$328K 0.05% 403

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Paradigm Asset Management's KERX Position: Q4 2014 in Review

Paradigm Asset Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2014, closing a stake of 21,700 shares — an estimated $298K sold.

Paradigm Asset Management first reported a position in KERX in Q4 2013 and held it in 4 quarters. The position peaked at $472K in Q2 2014. 147 funds tracked by Wall St. Rank hold KERX as of Q4 2014.

  • Paradigm Asset Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2014 after selling out during the quarter.
  • Paradigm Asset Management sold 21,700 Keryx Biopharmaceuticals Inc shares in Q4 2014, an estimated $298K.
  • Paradigm Asset Management first reported a position in Keryx Biopharmaceuticals Inc in Q4 2013 and held it in 4 quarters.
  • Paradigm Asset Management's Keryx Biopharmaceuticals Inc position peaked at $472K in Q2 2014.
  • 147 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2014.

Based on Paradigm Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.